Cargando…
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
Oridonin (Ori) is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens and has anti-inflammatory activity, but the target of Ori remains unknown. NLRP3 is a central component of NLRP3 inflammasome and has been involved in a wide variety of chronic inflammation-dri...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026158/ https://www.ncbi.nlm.nih.gov/pubmed/29959312 http://dx.doi.org/10.1038/s41467-018-04947-6 |
_version_ | 1783336397023739904 |
---|---|
author | He, Hongbin Jiang, Hua Chen, Yun Ye, Jin Wang, Aoli Wang, Chao Liu, Qingsong Liang, Gaolin Deng, Xianming Jiang, Wei Zhou, Rongbin |
author_facet | He, Hongbin Jiang, Hua Chen, Yun Ye, Jin Wang, Aoli Wang, Chao Liu, Qingsong Liang, Gaolin Deng, Xianming Jiang, Wei Zhou, Rongbin |
author_sort | He, Hongbin |
collection | PubMed |
description | Oridonin (Ori) is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens and has anti-inflammatory activity, but the target of Ori remains unknown. NLRP3 is a central component of NLRP3 inflammasome and has been involved in a wide variety of chronic inflammation-driven human diseases. Here, we show that Ori is a specific and covalent inhibitor for NLRP3 inflammasome. Ori forms a covalent bond with the cysteine 279 of NLRP3 in NACHT domain to block the interaction between NLRP3 and NEK7, thereby inhibiting NLRP3 inflammasome assembly and activation. Importantly, Ori has both preventive or therapeutic effects on mouse models of peritonitis, gouty arthritis and type 2 diabetes, via inhibition of NLRP3 activation. Our results thus identify NLRP3 as the direct target of Ori for mediating Ori’s anti-inflammatory activity. Ori could serve as a lead for developing new therapeutics against NLRP3-driven diseases. |
format | Online Article Text |
id | pubmed-6026158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60261582018-07-02 Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity He, Hongbin Jiang, Hua Chen, Yun Ye, Jin Wang, Aoli Wang, Chao Liu, Qingsong Liang, Gaolin Deng, Xianming Jiang, Wei Zhou, Rongbin Nat Commun Article Oridonin (Ori) is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens and has anti-inflammatory activity, but the target of Ori remains unknown. NLRP3 is a central component of NLRP3 inflammasome and has been involved in a wide variety of chronic inflammation-driven human diseases. Here, we show that Ori is a specific and covalent inhibitor for NLRP3 inflammasome. Ori forms a covalent bond with the cysteine 279 of NLRP3 in NACHT domain to block the interaction between NLRP3 and NEK7, thereby inhibiting NLRP3 inflammasome assembly and activation. Importantly, Ori has both preventive or therapeutic effects on mouse models of peritonitis, gouty arthritis and type 2 diabetes, via inhibition of NLRP3 activation. Our results thus identify NLRP3 as the direct target of Ori for mediating Ori’s anti-inflammatory activity. Ori could serve as a lead for developing new therapeutics against NLRP3-driven diseases. Nature Publishing Group UK 2018-06-29 /pmc/articles/PMC6026158/ /pubmed/29959312 http://dx.doi.org/10.1038/s41467-018-04947-6 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article He, Hongbin Jiang, Hua Chen, Yun Ye, Jin Wang, Aoli Wang, Chao Liu, Qingsong Liang, Gaolin Deng, Xianming Jiang, Wei Zhou, Rongbin Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title_full | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title_fullStr | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title_full_unstemmed | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title_short | Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity |
title_sort | oridonin is a covalent nlrp3 inhibitor with strong anti-inflammasome activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026158/ https://www.ncbi.nlm.nih.gov/pubmed/29959312 http://dx.doi.org/10.1038/s41467-018-04947-6 |
work_keys_str_mv | AT hehongbin oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT jianghua oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT chenyun oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT yejin oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT wangaoli oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT wangchao oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT liuqingsong oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT lianggaolin oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT dengxianming oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT jiangwei oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity AT zhourongbin oridoninisacovalentnlrp3inhibitorwithstrongantiinflammasomeactivity |